摘要
目的观察晚期食管癌患者应用奈达铂联合紫杉醇脂质体的临床疗效及安全性。方法采用分层随机分组法，将80例晚期食管癌患者分为研究组和对照组，每组40例。对照组采用奈达铂＋紫杉醇方案进行化疗，研究组采用奈达铂＋紫杉醇脂质体方案进行化疗。均以3周为1个疗程，比较2个疗程后两组患者的临床疗效、生命质量评分及不良反应发生情况。结果经过2个疗程治疗后，对照组治疗有效率为55．0％（22／40），研究组为57．5％（23／40），两组差异无统计学意义（Х^2=0．704，P〉0．05）。治疗前两组患者生命质量评分比较差异无统计学意义（t=0．794，P〉0．05）；经过1个疗程治疗后，两组患者生命质量均有所提升，但研究组提升程度优于对照组（t=5．782，P〈0．05）；经过2个疗程治疗后，两组患者生命质量均有所下降，差异无统计学意义（t=0．658，P〉0．05）。两组患者的白细胞减少、血小板减少、脱发及心电图变化方面差异均无统计学意义（均P〉0．05），但在恶心、呕吐、呼吸困难、肝损伤、肾损伤方面，研究组发生率低于对照组，差异均有统计学意义（均P〈0．05）。结论紫杉醇脂质体除保留紫杉醇原有药用机制、功效及适应证外，还能有效减轻后者带来的不良反应。其与奈达铂联合治疗晚期食管癌具有较好的疗效，且安全可靠，值得临床推广应用。
Objective To observe the clinical efficacy and safety of nedaplatin combined with paclitaxel liposome on advanced esophageal cancer. Methods 80 advanced esophageal cancer patients were divided randomly into two groups, including study group treated with nedaplatin and paclitaxel liposome and control group of chemotherapy with nedaplatin and paclitaxel regimen with 3-week as a course of treatment. The clinical efficacy, quality of life and adverse reaction were compared between both groups after 2 courses of treatment. Results After two courses of treatment, the effective rates in study group and control group were 57.5 % （23/40） and 55.0 % （22/40）, respectively, and there was no significant difference 0（z = 0.704, P 〉 0.05）. The quality of life score before the treatment had no significant difference between the two groups （t = 0.794, P 〉 0.05）. After one course of treatment, the quality of life was improved more than that in control group （t = 5.782, P 〈 0.05）. After two courses of treatment, the quality of life in both groups were decreased with no significant differences （t = 0.658, P 〈 0.05）. No statistical differences were found between the two groups in leucopenia, thrombocytopenia, alopecia and changes of electrocardiogram （all P 〉 0.05）, but the incidences of nausea and vomiting, dyspnea, liver function, renal function damage in study group were significantly lower than those in control group, and the differences were statistically significant （P 〈 0.05）. Conclusions Besides a favorable function in retention paclitaxel original medicinal mechanism, efficacy and indications, paclitaxel liposome can effectively avoid the risk of adverse events. Furthermore, paclitaxel liposome combined with nedaplatin for advanced esophageal cancer is worthy of wide application, due to the better curative effect and safety.
出处
《肿瘤研究与临床》
CAS
2016年第11期748-751,共4页
Cancer Research and Clinic
关键词
食管肿瘤
奈达铂
紫杉醇脂质体
安全性
Esophageal neoplasms
Nedaplatin
Paclitaxel liposome
Safety
